Zai Lab Ltd (ZLAB; NASDAQ: ZLAB; HKG: 9688), a leading biopharmaceutical company, is set to raise capital through a secondary public offering of American Depositary Shares (ADSs) valued at USD 230 million. The offering consists of 7,843,137 ADSs, with each ADS representing ten ordinary shares of the company, priced at USD 25.50 per share.
Details of the Offering and Underwriters’ Option
Furthermore, the underwriters have fully exercised their option to purchase an additional 1,176,470 ADSs at the public offering price, excluding underwriting discounts and commissions. The sale of these additional ADSs, following the exercise of the option, is anticipated to conclude on November 19, 2024, contingent upon the fulfillment of customary closing conditions.
Role of Joint Book-Running Managers
Goldman Sachs (Asia) L.L.C., Jefferies, and Leerink Partners have taken on the roles of joint book-running managers for this offering, providing their expertise in executing this capital raise.-Fineline Info & Tech
Leave a Reply